Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
THRD Stock Forecast 2026-2027
$5.38
Current Price
$242.79M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to THRD Price Targets
-44.2%
To High Target of $3.00
-44.2%
To Median Target of $3.00
-44.2%
To Low Target of $3.00
THRD Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-10.3%
1 Year Change
0.0%
Year-to-Date Change
-66.4%
From 52W High of $16.02
+69.2%
From 52W Low of $3.18
📊 TOP ANALYST CALLS
Did THRD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Third Harmonic Bio is one of their latest high-conviction picks.
Latest THRD Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, THRD has a neutral consensus with a median price target of $3.00 (ranging from $3.00 to $3.00). The overall analyst rating is N/A (N/A/10). Currently trading at $5.38, the median forecast implies a -44.2% downside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
THRD Analyst Ratings
0
Buy
1
Hold
0
Sell
THRD Price Target Range
Low
$3.00
Average
$3.00
High
$3.00
Current: $5.38
Latest THRD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for THRD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 28, 2025 | Stifel | Alex Thompson | Hold | Downgrade | $5.00 |
| Feb 12, 2025 | Morgan Stanley | Michael Ulz | Equal-Weight | Downgrade | $5.00 |
| Feb 11, 2025 | Raymond James | Laura Prendergast | Market Perform | Downgrade | $N/A |
| Aug 9, 2024 | Morgan Stanley | Michael Ulz | Overweight | Upgrade | $20.00 |
| Jun 18, 2024 | Stifel | Alex Thompson | Buy | Initiates | $23.00 |
| Jun 7, 2024 | Raymond James | Laura Prendergast | Outperform | Initiates | $18.00 |
| Aug 11, 2023 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $7.00 |
| Dec 16, 2022 | Morgan Stanley | Michael Ulz | Equal-Weight | Downgrade | $5.00 |
| Dec 16, 2022 | Jefferies | Akash Tewari | Hold | Downgrade | $3.60 |
| Oct 10, 2022 | Jefferies | Akash Tewari | Buy | Initiates | $30.00 |
| Oct 10, 2022 | Cowen & Co. | Joseph Thome | Outperform | Initiates | $N/A |
| Oct 10, 2022 | Morgan Stanley | Michael Ulz | Overweight | Initiates | $34.00 |
Third Harmonic Bio, Inc. (THRD) Competitors
The following stocks are similar to Third Harmonic Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
THRD
Third Harmonic Bio
mkt cap
242.79M
Third Harmonic Bio, Inc. (THRD) Financial Data
Third Harmonic Bio, Inc. has a market capitalization of $242.79M with a P/E ratio of 12.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -19.9%.
Valuation Metrics
Market Cap
$242.79M
Enterprise Value
$-25,821,452
P/E Ratio
12.5x
PEG Ratio
0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+111.9%
Current Ratio
54.1x
Debt/Equity
1.1x
ROE
-19.9%
ROA
-14.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Third Harmonic Bio, Inc. (THRD) Business Model
About Third Harmonic Bio, Inc.
What They Do
Develops therapeutics for allergic and inflammatory diseases.
Business Model
The company operates as a clinical-stage biopharmaceutical entity, primarily generating revenue through the development and commercialization of innovative therapeutics. Its focus on small molecule inhibitors allows it to target critical biological pathways associated with inflammatory responses, addressing significant unmet medical needs in high-demand therapeutic areas.
Additional Information
Third Harmonic Bio is strategically headquartered in the United States, facilitating its scientific and clinical development activities. The company's research is particularly relevant in the fields of immunology and respiratory health, where there is a pressing need for advanced treatments, positioning it as a key player in the healthcare and pharmaceuticals marketplace.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
31
CEO
Ms. Natalie C. Holles
Country
United States
IPO Year
2022
Website
www.thirdharmonicbio.comThird Harmonic Bio, Inc. (THRD) Latest News & Analysis
Latest News
Quick Summary
Third Harmonic Bio's stockholders approved liquidation at the June 5, 2025 meeting, expecting $5.30-$5.35 per share distribution in Q3 2025. The company is also selling its drug THB335.
Why It Matters
Stockholder approval for liquidation signals asset distribution, with expected payouts between $5.30-$5.35 per share. The initiation of THB335's sale adds potential value during dissolution.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Board of Directors has approved a liquidation plan and will seek stockholder approval for company dissolution at the Annual Meeting on June 5, 2025.
Why It Matters
The company's liquidation plan signals potential loss of shareholder value and may lead to stock price declines as investors anticipate dissolution.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Phase 1 data for THB335 in chronic spontaneous urticaria (CSU) supports progression to Phase 2 clinical trials.
Why It Matters
Positive Phase 1 data for THB335 suggests potential for effective CSU treatment, increasing its market viability and attractiveness for investors in biotech and pharmaceuticals.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10 months ago
Quick Summary
Third Harmonic Bio, Inc. (THRD) is in oversold territory, with analysts revising earnings estimates upward, suggesting a potential trend reversal.
Why It Matters
Third Harmonic Bio, Inc. (THRD) may be poised for a rebound due to oversold conditions and bullish earnings revisions, suggesting potential upside for investors.
Source: Zacks Investment Research
Market Sentiment:
Negative
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
11 months ago
Quick Summary
Third Harmonic Bio, Inc. (THRD) announced results from its Phase 1 trial of THB335, focusing on single and multiple ascending doses in healthy volunteers.
Why It Matters
The Phase 1 trial results for THB335 indicate progress in drug development for Third Harmonic Bio, which can influence stock performance and future investment decisions.
Source: Benzinga
Market Sentiment:
Negative
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
11 months ago
Quick Summary
Third Harmonic Bio, Inc. (THRD) is showing signs of being oversold, with Wall Street analysts revising earnings estimates higher, suggesting potential for a trend reversal.
Why It Matters
THRD's oversold status and upgraded earnings estimates signal potential for a price rebound, suggesting a favorable buying opportunity for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About THRD Stock
What is Third Harmonic Bio, Inc.'s (THRD) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Third Harmonic Bio, Inc. (THRD) has a median price target of $3.00. The highest price target is $3.00 and the lowest is $3.00.
Is THRD stock a good investment in 2026?
According to current analyst ratings, THRD has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for THRD stock?
Wall Street analysts predict THRD stock could reach $3.00 in the next 12 months. This represents a -44.2% decrease from the current price of $5.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Third Harmonic Bio, Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical entity, primarily generating revenue through the development and commercialization of innovative therapeutics. Its focus on small molecule inhibitors allows it to target critical biological pathways associated with inflammatory responses, addressing significant unmet medical needs in high-demand therapeutic areas.
What is the highest forecasted price for THRD Third Harmonic Bio, Inc.?
The highest price target for THRD is $3.00 from at , which represents a -44.2% decrease from the current price of $5.38.
What is the lowest forecasted price for THRD Third Harmonic Bio, Inc.?
The lowest price target for THRD is $3.00 from at , which represents a -44.2% decrease from the current price of $5.38.
What is the overall THRD consensus from analysts for Third Harmonic Bio, Inc.?
The overall analyst consensus for THRD is neutral. Out of 5 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are THRD stock price projections?
Stock price projections, including those for Third Harmonic Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 4:43 PM UTC